TY - JOUR
T1 - Stratifying a risk for an increased variation of airway caliber among the clinically stable asthma
AU - Hayata, Atsushi
AU - Matsunaga, Kazuto
AU - Hirano, Tsunahiko
AU - Akamatsu, Keiichiro
AU - Ichikawa, Tomohiro
AU - Minakata, Yoshiaki
AU - Ichinose, Masakazu
N1 - Funding Information:
The authors thank Mr. Brent Bell for reading the manuscript. This work was supported by the Grant of 2011 General Researches on Health Damage Caused by Air Pollution from the Environmental Restoration and Conservation Agency of Japan.
PY - 2013
Y1 - 2013
N2 - Background: Recently, correlations of peak expiratory flow (PEF) variation have been shown to facilitate the prediction of later asthma symptoms and exacerbations. However, it has not been fully examined whether or not any patient characteristics are associated with the residual airway lability in treated asthmatics. The objective of this study is to examine a predictive marker for increased variation of PEF in patients with clinically stable asthma. Methods: We studied 297 asthmatic patients who were monitored for PEF twice a day. Asthma Control Questionnaire (ACQ), spirometry, and exhaled nitric oxide fraction (FENO) were measured. After the assessment of baseline values, PEF measuring was continued and associations between these clinical markers and later variation of PEF over a week (Min%Max) were investigated. Results: 17.5% of the subjects showed increased PEF variability (Min%Max < 80%). ACQ, forced expiratory volume in 1 s % of predicted (%FEV1), and FENO were identified as independent predictors of Min%Max < 80%. An ACQ ≥ 0.4 yielded 96% sensitivity and 59% specificity, a %FEV1 ≤ 85% yielded 62% sensitivity and 89% specificity, and a FENO ≥ 40 ppb yielded 75% sensitivity and 90% specificity for identifying the subjects with high variability in PEF. When we combine %FEV1 ≤ 85% and FENO ≥ 40 ppb, this index showed the highest specificity (98%) for increased PEF variability. Conclusions: These results indicate that ACQ, %FEV1 and FENO can stratify the risk for increased variation in airway caliber among patients with stable asthma. This may help identify subjects in whom further monitoring of lung function fluctuations is indicated.
AB - Background: Recently, correlations of peak expiratory flow (PEF) variation have been shown to facilitate the prediction of later asthma symptoms and exacerbations. However, it has not been fully examined whether or not any patient characteristics are associated with the residual airway lability in treated asthmatics. The objective of this study is to examine a predictive marker for increased variation of PEF in patients with clinically stable asthma. Methods: We studied 297 asthmatic patients who were monitored for PEF twice a day. Asthma Control Questionnaire (ACQ), spirometry, and exhaled nitric oxide fraction (FENO) were measured. After the assessment of baseline values, PEF measuring was continued and associations between these clinical markers and later variation of PEF over a week (Min%Max) were investigated. Results: 17.5% of the subjects showed increased PEF variability (Min%Max < 80%). ACQ, forced expiratory volume in 1 s % of predicted (%FEV1), and FENO were identified as independent predictors of Min%Max < 80%. An ACQ ≥ 0.4 yielded 96% sensitivity and 59% specificity, a %FEV1 ≤ 85% yielded 62% sensitivity and 89% specificity, and a FENO ≥ 40 ppb yielded 75% sensitivity and 90% specificity for identifying the subjects with high variability in PEF. When we combine %FEV1 ≤ 85% and FENO ≥ 40 ppb, this index showed the highest specificity (98%) for increased PEF variability. Conclusions: These results indicate that ACQ, %FEV1 and FENO can stratify the risk for increased variation in airway caliber among patients with stable asthma. This may help identify subjects in whom further monitoring of lung function fluctuations is indicated.
KW - Airflow limitation
KW - Airway hyperresponsiveness
KW - Airway inflammation
KW - Airway lability
KW - Peak expiratory flow rate
UR - http://www.scopus.com/inward/record.url?scp=84884343474&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84884343474&partnerID=8YFLogxK
U2 - 10.2332/allergolint.13-OA-0543
DO - 10.2332/allergolint.13-OA-0543
M3 - Article
C2 - 23880616
AN - SCOPUS:84884343474
SN - 1323-8930
VL - 62
SP - 343
EP - 349
JO - Allergology International
JF - Allergology International
IS - 3
ER -